AstraZeneca's Lynparza gets FDA approval
20th May 2020 08:07
(Sharecast News) - Pharmaceutical giant AstraZeneca's drug Lynparza has been approved for the treatment of patients with a specific type of prostate cancer in the US.
Read moreAstraZeneca clears regulatory hurdles for Enhertu and Bevespi Aerosphere
18th May 2020 07:25
(Sharecast News) - AstraZeneca, alongside its partner Daiichi Sankyo, announced on Monday that 'Enhertu', or trastuzumab deruxtecan, has been granted breakthrough therapy designation in the United States.
Read moreMonday broker round-up
11th May 2020 13:48
(Sharecast News) - Diploma: Peel Hunt downgrades to hold with a target price of 1,650p.
Read moreAstraZeneca upbeat on developments for Lynparza, Enhertu
11th May 2020 07:29
(Sharecast News) - AstraZeneca, alongside its partner MSD, announced on Monday that 'Lynparza', or olaparib, in combination with bevacizumab has been approved in the United States for the maintenance treatment of adult patients with advanced epithelial ovarian, fallopian tube or primary peritoneal cancer.
Read moreAstraZeneca gets another approval for 'Farxiga'
6th May 2020 08:06
(Sharecast News) - AstraZeneca said on Wednesday that 'Farxiga', or dapagliflozin, has been approved in the United States to reduce the risk of cardiovascular death and hospitalisation for heart failure in adults with heart failure with reduced ejection fraction, with and without type-2 diabetes.
Read moreCredit Suisse ups AstraZeneca price target on lung cancer drug
30th Apr 2020 14:52
(Sharecast News) - Credit Suisse raised its target price for AstraZeneca to reflect the potential of the FTSE 100 company's Tagrisso lung cancer treatment.
Read moreThursday broker round-up
30th Apr 2020 13:16
(Sharecast News) - Mitchells & Butlers: JP Morgan upgrades to overweight with a target price of 340p.
Read moreAstraZeneca, Oxford University team up to develop Covid-19 vaccine
30th Apr 2020 10:07
(Sharecast News) - Pharma giant AstraZeneca said it had teamed up with the University of Oxford to develop and distribute a potential coronavirus vaccine with the first results from clinical trials set to arrive over the next few months.
Read moreAstraZeneca maintains FY guidance as Q1 revenues grow
29th Apr 2020 07:43
(Sharecast News) - AstraZeneca maintained its full-year guidance on Wednesday as it posted a rise in first-quarter profit and revenue.
Read moreWednesday preview: US Federal Reserve, Astra Zeneca in focus
28th Apr 2020 14:59
(Sharecast News) - The focus in the middle of the week will be on the US central bank with investors keen to know the Federal Reserve's take on the current state of economies and financial markets around the world.
Read moreMonday broker round-up
27th Apr 2020 13:54
(Sharecast News) - South32: Jefferies downgrades to underperform with a target price of 80p.
Read moreAstrazeneca's Lynparza shows promise in Phase III trial
24th Apr 2020 07:59
(Sharecast News) - Astrazeneca and Merck said their Lynparza prostate cancer treatment had met a second goal in a trial for patients suffering from the metastatic castration-resistant version of the disease.
Read moreAstraZeneca to trial diabetes drug on Covid-19 patients
23rd Apr 2020 13:12
(Sharecast News) - UK based pharma company AstraZeneca and Saint Luke's Mid America Heart Institute have started Phase III trials on the use of diabetes drug Farxiga to minimise the risk of serious complications from the Covid-19 disease.
Read moreResearch into Covid-19 antibody therapy gaining ground - report
20th Apr 2020 14:10
(Sharecast News) - Antibody therapy for Covid-19 may be available by the autumn, according to a report on biotechnology firms carrying out research.
Read moreWednesday broker round-up
15th Apr 2020 13:36
(Sharecast News) - Reckitt Benckiser Group: Credit Suisse upgrades to neutral with a target price of 5,900p.
Read more